Bailing Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11021014/publications.pdf Version: 2024-02-01



RAILING CHEN

#	Article	IF	CITATIONS
1	Mdig de-represses H19 large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3 and heterochromatin. Oncotarget, 2013, 4, 1427-1437.	0.8	87
2	JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic. Cell Cycle, 2013, 12, 112-121.	1.3	69
3	Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget, 2013, 4, 2430-2438.	0.8	60
4	JNK-Dependent Stat3 Phosphorylation Contributes to Akt Activation in Response to Arsenic Exposure. Toxicological Sciences, 2012, 129, 363-371.	1.4	58
5	Carcinogenic metalloid arsenic induces expression of mdig oncogene through JNK and STAT3 activation. Cancer Letters, 2014, 346, 257-263.	3.2	50
6	Arsenic-induced sub-lethal stress reprograms human bronchial epithelial cells to CD61Â ⁻ cancer stem cells. Oncotarget, 2014, 5, 1290-1303.	0.8	45
7	Reactive oxygen species contribute to arsenic-induced EZH2 phosphorylation in human bronchial epithelial cells and lung cancer cells. Toxicology and Applied Pharmacology, 2014, 276, 165-170.	1.3	34
8	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells. Journal of Medicinal Chemistry, 2016, 59, 7974-7990.	2.9	33
9	Loss of mdig expression enhances DNA and histone methylation and metastasis of aggressive breast cancer. Signal Transduction and Targeted Therapy, 2018, 3, 25.	7.1	32
10	Increased expression of mdig predicts poorer survival of the breast cancer patients. Gene, 2014, 535, 218-224.	1.0	31
11	Paradoxical Roles of Mineral Dust Induced Gene on Cell Proliferation and Migration/Invasion. PLoS ONE, 2014, 9, e87998.	1.1	31
12	Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. Molecular Pharmacology, 2016, 90, 225-237.	1.0	18
13	Targeting prostate cancer cells with enzalutamideâ€HDAC inhibitor hybrid drug 2â€75. Prostate, 2019, 79, 1166-1179.	1.2	15